Structure-Based Design of Non-Nucleoside Reverse Transcriptase Inhibitors of Drug-Resistant Human Immunodeficiency Virus

  title={Structure-Based Design of Non-Nucleoside Reverse Transcriptase Inhibitors of Drug-Resistant Human Immunodeficiency Virus},
  author={C. Mao and E. Sudbeck and T. Venkatachalam and F. Uckun},
  journal={Antiviral Chemistry and Chemotherapy},
  pages={233 - 240}
  • C. Mao, E. Sudbeck, +1 author F. Uckun
  • Published 1999
  • Medicine, Biology
  • Antiviral Chemistry and Chemotherapy
  • A computer model of reverse transcriptase (RT) from human immunodeficiency virus type 1 (HIV-1) was used to design thiourea compounds that were predicted to inhibit RT. The RT model was used to approximate how changes in binding pocket shape, volume and chemical properties resulting from residue mutations would affect inhibitor binding. Our lead compound, N-[2-(2,5-dime-thoxyphenylethyl)]-N′-[2-(5-bromopyridyl)]-thiourea (HI-236) was tested against clinically observed non-nucleoside inhibitor… CONTINUE READING
    33 Citations
    Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase
    • O. D'cruz, F. Uckun
    • Biology, Medicine
    • Journal of enzyme inhibition and medicinal chemistry
    • 2006
    • 22
    Discovery of 2,5-dimethoxy-substituted 5-bromopyridyl thiourea (PHI-236) as a potent broad-spectrum anti-human immunodeficiency virus microbicide.
    • 20
    • PDF
    The search for potent, small molecule NNRTIs: A review.
    • 57
    Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds.
    • 57
    Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
    • 96
    • PDF


    Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor.
    • R. Esnouf, J. Ren, +4 authors D. Stuart
    • Biology, Medicine
    • Proceedings of the National Academy of Sciences of the United States of America
    • 1997
    • 168
    • PDF
    The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
    • 82
    • PDF
    Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro
    • 159
    Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.
    • 341
    • PDF
    Molecular modeling studies of HIV‐1 reverse transcriptase nonnucleoside inhibitors: Total energy of complexation as a predictor of drug placement and activity
    • 58